Leerink Partnrs Decreases Earnings Estimates for MannKind

MannKind Co. (NASDAQ:MNKD) – Investment analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for MannKind in a report released on Wednesday, December 18th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings of $0.22 per share for the year, down from their previous forecast of $0.23. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for MannKind’s current full-year earnings is $0.10 per share.

Other analysts have also issued reports about the stock. Oppenheimer upped their price objective on shares of MannKind from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Leerink Partners began coverage on MannKind in a research note on Monday, September 9th. They set an “outperform” rating and a $8.00 price target for the company. StockNews.com downgraded MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 7th. Wells Fargo & Company started coverage on MannKind in a research note on Friday. They issued an “overweight” rating and a $9.00 price objective on the stock. Finally, Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $7.00 to $10.00 in a research report on Thursday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $8.88.

MannKind Price Performance

Shares of MNKD opened at $6.85 on Friday. The stock has a market capitalization of $1.89 billion, a P/E ratio of 97.86 and a beta of 1.28. MannKind has a 12-month low of $3.17 and a 12-month high of $7.63. The firm’s 50 day moving average is $6.75 and its 200-day moving average is $6.01.

Institutional Trading of MannKind

Institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. raised its holdings in shares of MannKind by 401.8% during the 3rd quarter. Principal Financial Group Inc. now owns 168,518 shares of the biopharmaceutical company’s stock worth $1,060,000 after buying an additional 134,937 shares in the last quarter. Franklin Resources Inc. raised its position in shares of MannKind by 3.0% in the 3rd quarter. Franklin Resources Inc. now owns 160,016 shares of the biopharmaceutical company’s stock worth $1,047,000 after acquiring an additional 4,603 shares in the last quarter. Geode Capital Management LLC boosted its stake in MannKind by 0.4% during the third quarter. Geode Capital Management LLC now owns 6,338,928 shares of the biopharmaceutical company’s stock worth $39,880,000 after acquiring an additional 24,031 shares in the last quarter. Barclays PLC raised its stake in MannKind by 186.0% during the 3rd quarter. Barclays PLC now owns 519,865 shares of the biopharmaceutical company’s stock worth $3,271,000 after buying an additional 338,121 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new stake in MannKind during the 3rd quarter valued at $413,000. Institutional investors own 49.55% of the company’s stock.

Insider Activity

In other MannKind news, Director Steven B. Binder sold 67,539 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $6.76, for a total transaction of $456,563.64. Following the completion of the transaction, the director now owns 1,075,026 shares in the company, valued at approximately $7,267,175.76. This represents a 5.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stuart A. Tross sold 55,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total transaction of $403,700.00. Following the transaction, the insider now directly owns 967,191 shares of the company’s stock, valued at $7,099,181.94. This represents a 5.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 190,075 shares of company stock valued at $1,325,587. 3.00% of the stock is currently owned by insiders.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.